España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Amneal Pharmaceuticals
AMRX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$8.26
0.00
0.00%
Pre-Market: Jan 17, 4:00 PM EDT
Get Report
Comment
Amneal Pharmaceuticals (AMRX) Forecast
News
Earnings
Amneal Pharmaceuticals (AMRX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock
Amneal Pharmaceuticals Stock (NASDAQ: AMRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, January 15, 2025
Amneal Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Amneal Pharmaceuticals Expects To Meet Its 20...
Benzinga Newsdesk
Monday, January 06, 2025
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
Vandana Singh
Thursday, November 21, 2024
Amneal Resubmits DHE Autoinjector New Drug Ap...
Benzinga Newsdesk
Monday, November 11, 2024
Amneal Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Piper Sandler Maintains Overweight on Amneal ...
Benzinga Newsdesk
Friday, November 08, 2024
Amneal Pharmaceuticals shares are trading low...
Benzinga Newsdesk
Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts
Vandana Singh
Amneal Reaffirms 2024 Revenue Guidance Of $2....
Benzinga Newsdesk
Amneal Pharmaceuticals Q3 2024 Adj EPS $0.16 ...
Benzinga Newsdesk
Thursday, November 07, 2024
Earnings Outlook For Amneal Pharmaceuticals
Benzinga Insights
What's Next: Amneal Pharmaceuticals's Earnings Preview
Benzinga Insights
Monday, October 21, 2024
Amneal Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Amneal Receives U.S. FDA Approval Of New Drug...
Benzinga Newsdesk
Wednesday, October 02, 2024
Truist Securities Maintains Buy on Amneal Pha...
Benzinga Newsdesk
Tuesday, October 01, 2024
Amneal, Metsera Enter Collaboration Agreement...
Benzinga Newsdesk
Monday, September 23, 2024
Amneal Launches CREXONT Extended-Release Caps...
Benzinga Newsdesk
Friday, September 06, 2024
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Vandana Singh
JP Morgan Upgrades Amneal Pharmaceuticals to ...
Benzinga Newsdesk
Thursday, September 05, 2024
Amneal And Shilpa Receive FDA Approval For BO...
Benzinga Newsdesk
Tuesday, August 20, 2024
Amneal Announces FDA Approval For Propofol In...
Benzinga Newsdesk
Tuesday, August 13, 2024
Barclays Maintains Overweight on Amneal Pharm...
Benzinga Newsdesk
Monday, August 12, 2024
Truist Securities Maintains Buy on Amneal Pha...
Benzinga Newsdesk
Friday, August 09, 2024
Amneal Expects 2024 Adjusted EPS Of $0.57-$0....
Benzinga Newsdesk
Amneal Expects 2024 Revenues Of $2.70B-$2.80B...
Benzinga Newsdesk
Amneal Pharmaceuticals Q2 2024 Adj. EPS $0.16...
Benzinga Newsdesk
Wednesday, August 07, 2024
Amneal Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Amneal Receives FDA Approval for IPX203 For P...
Benzinga Newsdesk
Monday, July 29, 2024
Amneal Pharmaceuticals Receives FDA Approval ...
Benzinga Newsdesk
Tuesday, July 09, 2024
Amneal Pharmaceuticals Launches Focinvez, Rea...
Benzinga Newsdesk
Monday, July 01, 2024
Kashiv BioSciences Enters Into Exclusive Lice...
Benzinga Newsdesk
Tuesday, June 11, 2024
Reported Monday June 10, 2024 "Amneal, U.S. F...
Benzinga Newsdesk
Wednesday, June 05, 2024
Amneal Expands Broad Injectables Portfolio Wi...
Benzinga Newsdesk
Wednesday, May 22, 2024
Amneal Has Begun Supplying OTC Naloxone Hydro...
Benzinga Newsdesk
Monday, May 06, 2024
Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts
Benzinga Insights
Goldman Sachs Maintains Buy on Amneal Pharmac...
Benzinga Newsdesk
Truist Securities Reiterates Buy on Amneal Ph...
Benzinga Newsdesk
Friday, May 03, 2024
Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement
Vandana Singh
CORRECTION: Amneal Reaffirms 2024 Revenue Gui...
Benzinga Newsdesk
Amneal Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Amneal Pharmaceuticals Q1 2024 Adj EPS $0.14 ...
Benzinga Newsdesk
Wednesday, April 24, 2024
Amneal Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Amneal Announces FDA Approval Of Over-The-Cou...
Benzinga Newsdesk
Tuesday, April 16, 2024
Amneal Launches PEMRYDI RTU, The First Ready-...
Benzinga Newsdesk
Friday, April 05, 2024
Bausch Health Announces Patent Lawsuit Agains...
Benzinga Newsdesk
Monday, March 25, 2024
Amneal Receives FDA Approval For Ciprofloxaci...
Benzinga Newsdesk
Friday, March 22, 2024
FTC Files Amicus Brief in Asthma Inhaler Pate...
Benzinga Newsdesk
Thursday, March 21, 2024
Piper Sandler Maintains Overweight on Amneal ...
Benzinga Newsdesk
Monday, March 04, 2024
Goldman Sachs Maintains Buy on Amneal Pharmac...
Benzinga Newsdesk
Friday, March 01, 2024
Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?
Vandana Singh
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
